share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director George Simeon

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director George Simeon

CRISPR Therapeutics | 4：持股變動聲明-董事 George Simeon
美股sec公告 ·  06/01 04:54
牛牛AI助理已提取核心訊息
In a recent transaction, George Simeon engaged with CRISPR Therapeutics AG, trading under the symbol CRSP, on May 30, 2024. The details of the transaction, including the number of shares involved and the nature of the transaction, have not been disclosed. As of now, the relationship of George Simeon to the issuer remains unspecified. Investors are advised to note the date of the transaction for their records.
In a recent transaction, George Simeon engaged with CRISPR Therapeutics AG, trading under the symbol CRSP, on May 30, 2024. The details of the transaction, including the number of shares involved and the nature of the transaction, have not been disclosed. As of now, the relationship of George Simeon to the issuer remains unspecified. Investors are advised to note the date of the transaction for their records.
在最近的一筆交易中，喬治·西蒙於2024年5月30日與CRISPR Therapeutics AG進行了交易，股票代碼爲CRSP。該交易的細節，包括所涉及的股票數量和交易的性質，尚未披露。截至目前，喬治·西蒙與發行人的關係仍未明確。建議投資者記下交易日期以備記錄。
在最近的一筆交易中，喬治·西蒙於2024年5月30日與CRISPR Therapeutics AG進行了交易，股票代碼爲CRSP。該交易的細節，包括所涉及的股票數量和交易的性質，尚未披露。截至目前，喬治·西蒙與發行人的關係仍未明確。建議投資者記下交易日期以備記錄。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。